Corvus Pharmaceuticals, Inc. - CRVS
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 07, 2026 | SCHEDULE 13G | STATE STREET CORPORATION | 5.3% | 4,474,091 | View |
| Jul 27, 2026 | SCHEDULE 13G/A | BlackRock, Inc. | 7.5% | 6,325,157 | View |
| May 15, 2026 | SCHEDULE 13G/A | Point72 Asset Management, L.P. | 0.0% | 0 | View |
| May 15, 2026 | SCHEDULE 13G/A | Point72 Capital Advisors, Inc. | 0.0% | 0 | View |
| May 15, 2026 | SCHEDULE 13G/A | Steven A. Cohen | 0.0% | 0 | View |
| May 15, 2026 | SCHEDULE 13G | Sirenia Capital Management LP | 7.5% | 6,831,828 | View |
| May 15, 2026 | SCHEDULE 13G | Alex Silverstein | 7.5% | 6,831,828 | View |
| Apr 27, 2026 | SCHEDULE 13G/A | BlackRock, Inc. | 6.4% | 5,387,818 | View |
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.